Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Victrelis
Boceprevir is an antiviral medication specifically designed to treat chronic hepatitis C virus (HCV) genotype 1 infection. It belongs to a class of drugs known as protease inhibitors, which work by blocking the activity of a viral enzyme essential for HCV replication. Boceprevir was groundbreaking as one of the first direct-acting antiviral agents (DAAs) approved for HCV, significantly improving treatment outcomes compared to older interferon-based regimens. However, it has largely been replaced by newer, more effective and better-tolerated DAAs.
For the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin.
Severe anemia and/or neutropenia have been observed in patients treated with boceprevir in combination with peginterferon alfa and ribavirin.
Outcome:
Reduced boceprevir levels, potential treatment failure
Mechanism:
CYP3A4 induction
Outcome:
Reduced boceprevir absorption
Mechanism:
Chelation/altered pH
Outcome:
Potential for reduced boceprevir absorption
Mechanism:
Chelation/mineral interaction
No significant new formulations or indications for boceprevir are anticipated.
Based on historical usage and the availability of newer DAAs, the likelihood of boceprevir being prescribed for HCV is extremely low.
Antiviral, Protease Inhibitor
Ketoamide